董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ho Ching Chen | 男 | Director | 69 | 未披露 | 未持股 | 2025-12-11 |
| Pei Wen Chou | 男 | Director | 58 | 未披露 | 84.00 | 2025-12-11 |
| Hann Chyi Lin | 男 | Independent Director | 74 | 未披露 | 5.00 | 2025-12-11 |
| Tai Nang Huang | 男 | Independent Director | 75 | 未披露 | 未持股 | 2025-12-11 |
| Yin Ho Huang | 男 | Independent Director | 66 | 未披露 | 0.10 | 2025-12-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tza Zen Chaung | 男 | Chief Executive Officer | 73 | 未披露 | 1.00 | 2025-12-11 |
| Pi Chuan Chien | 男 | Chief Financial Officer | 58 | 未披露 | 未持股 | 2025-12-11 |
| Yu Fang Hu | 男 | Chief Operating Officer | 63 | 未披露 | 未持股 | 2025-12-11 |
| Jen Wei Liu | 男 | Chief Scientific Officer | 42 | 未披露 | 12.50 | 2025-12-11 |
| Yuan Sheng Li | 男 | Chief Technology Officer | 41 | 未披露 | 12.70 | 2025-12-11 |
董事简历
中英对照 | 中文 | 英文- Ho Ching Chen
-
Ho Ching Chen，现任子公司顾问和董事，自2010年12月起兼任这两个职务。Chen先生是一名投资者，曾投资于休闲行业、半导体行业、环保行业、生物科技和制药行业的公司。Chen先生亦是以下公司的创办人：台湾休闲产业公司向日葵假日股份有限公司；台湾半导体产业公司Chiplus Semiconductor Corp.；台湾环保产业公司TMG Group Wanji Technology Co.，Ltd.；新加坡环保产业公司Singapore Enviro-Hub Holding Ltd.；台湾生物科技及医药产业公司Baining Biotech Co.，Ltd.；台湾生物科技及医药产业公司Guang-Li Biomedicine Inc.（于2023年1月13日实现更名为“Xi Yue Biomedicine Inc.”）。Chen先生是主要投资者，曾于2015年1月至2021年1月担任台湾休闲产业公司阿里山酒店有限公司的董事长。因为家庭的痛苦，他渴望回馈社会，专注于癌症、神经退行性疾病和罕见病等新药的研发，希望造福受疾病影响的社区。Chen先生于2005年获得台湾清运大学国际工商管理学位。Chen先生于2009年获得中国暨南大学工商管理硕士学位。
Ho Ching Chen is founder, and he currently serves as a Director of the Company. Mr. Chen also currently serves as a Consultant and Director of the Subsidiary and has served in both roles since December 2010. Mr. Chen is an investor and has invested in companies in the leisure indtry, semiconductor indtry, environmental protection indtry, and the biotechnology and pharmaceutical indtry. Mr. Chen is also the founder of: Sunflor Holiday Co., Ltd., a leisure indtry company in Taiwan; Chipl Semiconductor Corp., a semiconductor indtry company in Taiwan; Tmg Group Wanji Technology Co., Ltd., an environmental protection indtry company in Taiwan; Singapore Enviro Hub holding Ltd., an environmental protection indtry company in Singapore; Baining Biotech Co., Ltd., a biotechnology and pharmaceutical indtry company in Taiwan; and Guang Li Biomedicine Inc.(which effected a name change to "Xi Yue Biomedicine Inc." on January 13, 2023), a biotechnology and pharmaceutical indtry company in Taiwan. Mr. Chen was a major investor and served as chairman of Alishan Hotel Co., Ltd., a leisure indtry company in Taiwan, from January 2015 to January 2021. Becae of the pain of his family, he aspired to give back to the society, focing on the development of new drugs such as cancer, neurodegenerative and rare diseases, hoping to benefit the community affected by diseases. Mr. Chen obtained a degree in international biness administration from Ching Yun University in Taiwan, in 2005. Mr. Chen obtained a Master of Biness Administration degree from Jinan University in China, in 2009. - Ho Ching Chen，现任子公司顾问和董事，自2010年12月起兼任这两个职务。Chen先生是一名投资者，曾投资于休闲行业、半导体行业、环保行业、生物科技和制药行业的公司。Chen先生亦是以下公司的创办人：台湾休闲产业公司向日葵假日股份有限公司；台湾半导体产业公司Chiplus Semiconductor Corp.；台湾环保产业公司TMG Group Wanji Technology Co.，Ltd.；新加坡环保产业公司Singapore Enviro-Hub Holding Ltd.；台湾生物科技及医药产业公司Baining Biotech Co.，Ltd.；台湾生物科技及医药产业公司Guang-Li Biomedicine Inc.（于2023年1月13日实现更名为“Xi Yue Biomedicine Inc.”）。Chen先生是主要投资者，曾于2015年1月至2021年1月担任台湾休闲产业公司阿里山酒店有限公司的董事长。因为家庭的痛苦，他渴望回馈社会，专注于癌症、神经退行性疾病和罕见病等新药的研发，希望造福受疾病影响的社区。Chen先生于2005年获得台湾清运大学国际工商管理学位。Chen先生于2009年获得中国暨南大学工商管理硕士学位。
- Ho Ching Chen is founder, and he currently serves as a Director of the Company. Mr. Chen also currently serves as a Consultant and Director of the Subsidiary and has served in both roles since December 2010. Mr. Chen is an investor and has invested in companies in the leisure indtry, semiconductor indtry, environmental protection indtry, and the biotechnology and pharmaceutical indtry. Mr. Chen is also the founder of: Sunflor Holiday Co., Ltd., a leisure indtry company in Taiwan; Chipl Semiconductor Corp., a semiconductor indtry company in Taiwan; Tmg Group Wanji Technology Co., Ltd., an environmental protection indtry company in Taiwan; Singapore Enviro Hub holding Ltd., an environmental protection indtry company in Singapore; Baining Biotech Co., Ltd., a biotechnology and pharmaceutical indtry company in Taiwan; and Guang Li Biomedicine Inc.(which effected a name change to "Xi Yue Biomedicine Inc." on January 13, 2023), a biotechnology and pharmaceutical indtry company in Taiwan. Mr. Chen was a major investor and served as chairman of Alishan Hotel Co., Ltd., a leisure indtry company in Taiwan, from January 2015 to January 2021. Becae of the pain of his family, he aspired to give back to the society, focing on the development of new drugs such as cancer, neurodegenerative and rare diseases, hoping to benefit the community affected by diseases. Mr. Chen obtained a degree in international biness administration from Ching Yun University in Taiwan, in 2005. Mr. Chen obtained a Master of Biness Administration degree from Jinan University in China, in 2009.
- Pei Wen Chou
-
Pei Wen Chou，现任该子公司首席执行官兼总裁，自2010年12月起担任这些职务。Chou博士目前还担任台湾生物科技公司Hawking Biological Technology Co. Ltd的总裁和董事，分别自2013年1月和2010年12月起担任这些职务。Chou博士此前曾于2011年2月至2014年7月担任光力生物医药股份有限公司董事长。Chou博士拥有20年临床实践、生物技术公司的建立和管理经验，并担任执业护士。为此，Chou医生此前曾于1993年至2002年在某医疗中心担任心脏外科团队和重症监护病房（ICU）专家/组长。Chou博士于1987年获得台湾德育学院护理与健康学士学位。Chou博士于2001年获得诺贝尔学院医学研究生院硕士学位。Chou博士于2005年获得马来西亚塔曼大学顺势疗法医学博士学位。
Pei Wen Chou has served as a Director of the Company since April 13, 2023. Dr. Chou also currently serves as Chief Executive Officer and President of the Subsidiary and has served in these roles since December 2010. Dr. Chou also currently serves as President and Director of Hawking Biological Technology Co. Ltd, a biotechnology company in Taiwan, and has served in these roles since January 2013 and December 2010, respectively. Dr. Chou previoly served as chairman of Guang Li Biomedicine Inc. from February 2011 to July 2014. Dr. Chou has 20 years of experience in clinical practice, establishment and management of biotech companies, and as a nurse practitioner. To this end, Dr. Chou previoly served as Specialist/Leader of the cardiac surgery team and intensive care units (IC) in a medical center from 1993 to 2002. Dr. Chou obtained a Bachelor's degree in nursing and health from Deh Yu College in Taiwan, in 1987. Dr. Chou obtained a Master's degree from the graduate institute of medicine of Nobel College in 2001. Dr. Chou obtained a Ph.D. degree in homeopathy medicine from Taman University in Malaysia, in 2005. - Pei Wen Chou，现任该子公司首席执行官兼总裁，自2010年12月起担任这些职务。Chou博士目前还担任台湾生物科技公司Hawking Biological Technology Co. Ltd的总裁和董事，分别自2013年1月和2010年12月起担任这些职务。Chou博士此前曾于2011年2月至2014年7月担任光力生物医药股份有限公司董事长。Chou博士拥有20年临床实践、生物技术公司的建立和管理经验，并担任执业护士。为此，Chou医生此前曾于1993年至2002年在某医疗中心担任心脏外科团队和重症监护病房（ICU）专家/组长。Chou博士于1987年获得台湾德育学院护理与健康学士学位。Chou博士于2001年获得诺贝尔学院医学研究生院硕士学位。Chou博士于2005年获得马来西亚塔曼大学顺势疗法医学博士学位。
- Pei Wen Chou has served as a Director of the Company since April 13, 2023. Dr. Chou also currently serves as Chief Executive Officer and President of the Subsidiary and has served in these roles since December 2010. Dr. Chou also currently serves as President and Director of Hawking Biological Technology Co. Ltd, a biotechnology company in Taiwan, and has served in these roles since January 2013 and December 2010, respectively. Dr. Chou previoly served as chairman of Guang Li Biomedicine Inc. from February 2011 to July 2014. Dr. Chou has 20 years of experience in clinical practice, establishment and management of biotech companies, and as a nurse practitioner. To this end, Dr. Chou previoly served as Specialist/Leader of the cardiac surgery team and intensive care units (IC) in a medical center from 1993 to 2002. Dr. Chou obtained a Bachelor's degree in nursing and health from Deh Yu College in Taiwan, in 1987. Dr. Chou obtained a Master's degree from the graduate institute of medicine of Nobel College in 2001. Dr. Chou obtained a Ph.D. degree in homeopathy medicine from Taman University in Malaysia, in 2005.
- Hann Chyi Lin
-
Hann Chyi Lin，现任台湾合作金库金融控股股份有限公司独立董事，自2020年6月起担任该职务。Lin先生于2005年2月至2006年4月担任第一银行（First Bank）香港分行经理，并于2007年2月至2009年3月再次担任。Lin先生于2002年2月至2005年2月担任台湾地区第一银行（First Bank）国际部经理。Lin先生于1997年7月至2001年8月担任第一银行（First Bank）新加坡分行经理。Lin先生于1976年3月至1979年9月期间受雇于第一商业银行股份有限公司（“First Bank”）在台湾的万华分行。2014年10月至2016年11月任台湾第一证券公司董事长。Lin先生精通银行外汇资金运作、国外分支机构的运营管理，在金融控股公司、银行和证券公司的内部控制、审计系统运作和整体运营管理方面具有丰富的经验。Lin先生于1973年在台湾丰嘉大学取得统计学学士学位。
Hann Chyi Lin was appointed as Independent Director of the Company on April 13, 2023. Mr. Lin also currently serves as Independent Director of Taiwan Cooperative Financial Holding Co., Ltd. in Taiwan, and has served in this role since June 2020. Mr. Lin served as Manager of First Bank's Hong Kong branch from February 2005 to April 2006 and again from February 2007 to March 2009. Mr. Lin served as Manager of the international department of First Bank in Taiwan from February 2002 to February 2005. Mr. Lin served as Manager of First Bank in its Singapore branch from July 1997 to August 2001. Mr. Lin was employed by First Commercial Bank Co., Ltd. ("First Bank") in its Wanhua branch in Taiwan from March 1976 to September 1979. He served as Chairman of First Securities Incorporation in Taiwan from October 2014 to November 2016. Mr. Lin obtained a Bachelor's degree in statistics from Feng Chia University in Taiwan in 1973. - Hann Chyi Lin，现任台湾合作金库金融控股股份有限公司独立董事，自2020年6月起担任该职务。Lin先生于2005年2月至2006年4月担任第一银行（First Bank）香港分行经理，并于2007年2月至2009年3月再次担任。Lin先生于2002年2月至2005年2月担任台湾地区第一银行（First Bank）国际部经理。Lin先生于1997年7月至2001年8月担任第一银行（First Bank）新加坡分行经理。Lin先生于1976年3月至1979年9月期间受雇于第一商业银行股份有限公司（“First Bank”）在台湾的万华分行。2014年10月至2016年11月任台湾第一证券公司董事长。Lin先生精通银行外汇资金运作、国外分支机构的运营管理，在金融控股公司、银行和证券公司的内部控制、审计系统运作和整体运营管理方面具有丰富的经验。Lin先生于1973年在台湾丰嘉大学取得统计学学士学位。
- Hann Chyi Lin was appointed as Independent Director of the Company on April 13, 2023. Mr. Lin also currently serves as Independent Director of Taiwan Cooperative Financial Holding Co., Ltd. in Taiwan, and has served in this role since June 2020. Mr. Lin served as Manager of First Bank's Hong Kong branch from February 2005 to April 2006 and again from February 2007 to March 2009. Mr. Lin served as Manager of the international department of First Bank in Taiwan from February 2002 to February 2005. Mr. Lin served as Manager of First Bank in its Singapore branch from July 1997 to August 2001. Mr. Lin was employed by First Commercial Bank Co., Ltd. ("First Bank") in its Wanhua branch in Taiwan from March 1976 to September 1979. He served as Chairman of First Securities Incorporation in Taiwan from October 2014 to November 2016. Mr. Lin obtained a Bachelor's degree in statistics from Feng Chia University in Taiwan in 1973.
- Tai Nang Huang
-
Tai Nang Huang，现任Linden Technologies，Inc.总经理，自2000年4月起担任该职务。黄博士曾担任Pyrexar Medical Inc.董事会成员。黄博士在用于癌症生物标志物发现和新药研究的基因芯片创新以及药物代谢研究方面拥有丰富的经验。黄博士于1972年获得国立台湾大学化学理学学士学位。黄博士于1977年获得德国格廷根大学化学理学硕士学位。黄博士于1980年在澳大利亚的澳大利亚国立大学获得化学博士学位。黄博士于1980年至1982年在普林斯顿大学担任博士后研究助理。
Tai Nang Huang was appointed as Independent Director of the Company on April 13, 2023. Dr. Huang currently serves as General Manager of Linden Technologies, Inc. and has served in this role since April 2000. Dr. Huang has served as a member of the board of directors of Pyrexar Medical Inc. Dr. Huang has extensive experience in gene chip innovation for cancer biomarker discovery and new drug research, and drug metabolism investigations. Dr. Huang obtained a Bachelor of Science degree in chemistry from National Taiwan University, in 1972. Dr. Huang obtained a Master of Science degree in chemistry from the University of Goettingen in Germany, in 1977. Dr. Huang obtained a Ph.D. degree in chemistry from the Atralian National University, in Atralia, in 1980. Dr. Huang was a postdoctoral research associate at Princeton University from 1980 to 1982. - Tai Nang Huang，现任Linden Technologies，Inc.总经理，自2000年4月起担任该职务。黄博士曾担任Pyrexar Medical Inc.董事会成员。黄博士在用于癌症生物标志物发现和新药研究的基因芯片创新以及药物代谢研究方面拥有丰富的经验。黄博士于1972年获得国立台湾大学化学理学学士学位。黄博士于1977年获得德国格廷根大学化学理学硕士学位。黄博士于1980年在澳大利亚的澳大利亚国立大学获得化学博士学位。黄博士于1980年至1982年在普林斯顿大学担任博士后研究助理。
- Tai Nang Huang was appointed as Independent Director of the Company on April 13, 2023. Dr. Huang currently serves as General Manager of Linden Technologies, Inc. and has served in this role since April 2000. Dr. Huang has served as a member of the board of directors of Pyrexar Medical Inc. Dr. Huang has extensive experience in gene chip innovation for cancer biomarker discovery and new drug research, and drug metabolism investigations. Dr. Huang obtained a Bachelor of Science degree in chemistry from National Taiwan University, in 1972. Dr. Huang obtained a Master of Science degree in chemistry from the University of Goettingen in Germany, in 1977. Dr. Huang obtained a Ph.D. degree in chemistry from the Atralian National University, in Atralia, in 1980. Dr. Huang was a postdoctoral research associate at Princeton University from 1980 to 1982.
- Yin Ho Huang
-
Yin Ho Huang，现任Tianxia Law Firm主任，自1993年1月起担任该职务。在加入Tianxia Law Firm之前，Huang先生于1992年3月至1993年2月在台湾Jiying Law Firm担任律师。Huang先生目前是台湾的执业律师和专利代理律师。Huang先生于1988年获得台湾国立台湾大学法律系学士学位。
Yin Ho Huang was appointed as Independent Director of the Company on April 13, 2023. Mr. Huang currently serves as the Director of Tianxia Law Firm and has served in this role since January 1993.Prior to joining Tianxia Law Firm, Mr. Huang was a lawyer with Jiying Law Firm in Taiwan from March 1992 to February1993. Mr. Huang is currently a practicing lawyer and patent attorney in Taiwan. Mr. Huang obtained his Bachelor's degree from the Law Department of National Taiwan University in Taiwan in 1988. - Yin Ho Huang，现任Tianxia Law Firm主任，自1993年1月起担任该职务。在加入Tianxia Law Firm之前，Huang先生于1992年3月至1993年2月在台湾Jiying Law Firm担任律师。Huang先生目前是台湾的执业律师和专利代理律师。Huang先生于1988年获得台湾国立台湾大学法律系学士学位。
- Yin Ho Huang was appointed as Independent Director of the Company on April 13, 2023. Mr. Huang currently serves as the Director of Tianxia Law Firm and has served in this role since January 1993.Prior to joining Tianxia Law Firm, Mr. Huang was a lawyer with Jiying Law Firm in Taiwan from March 1992 to February1993. Mr. Huang is currently a practicing lawyer and patent attorney in Taiwan. Mr. Huang obtained his Bachelor's degree from the Law Department of National Taiwan University in Taiwan in 1988.
高管简历
中英对照 | 中文 | 英文- Tza Zen Chaung
Tza Zen Chaung，在新药开发、药品良好生产规范（“GMP”）、制造工艺开发以及研发管理和战略方面拥有40年的经验。在担任Everfront Biotech Holding Company Limited的首席执行官之前，Chaung博士于1982年8月至1989年8月在新泽西州Rahway的默克公司（在美国和加拿大以外的国家称为默沙东）担任高级工程师，从事新药开发工作。1991年6月至1992年8月，他在新泽西州纳特利的Hoffmann-La Roche担任研究调查员。1992年8月至1995年1月在新泽西州新不伦瑞克的百时美施贵宝担任组长。从1995年1月至2023年1月，Chaung博士一直在美国和台湾担任制药和生物技术行业顾问。Chaung博士于1974年获得台湾国立台湾大学化学工程学理学学士学位。Chaung博士于1978年获得西弗吉尼亚州西弗吉尼亚大学化学工程理学硕士学位。Chaung博士于1982年在马萨诸塞州剑桥的麻省理工学院获得理学博士学位。
Tza Zen Chaung serves as Chief Executive Officer and has served in this role since January 2023. Dr. Chaung has 40 years of experience in new drug development, pharmaceutical good manufacturing practice ("GMP"), manufacturing process development, and R&D management and strategy. Prior to serving as Chief Executive Officer, Dr. Chaung was Senior Engineer at Merck & Company in Rahway, New Jersey from August 1982 to August 1989, where he worked on new drug development. He worked as Research Investigator with Hoffmann La Roche in Nutley, New Jersey from June 1991 to August 1992. He worked as Group Leader with Bristol Myers Squibb in New Brunswick, New Jersey from August 1992 to January 1995. Dr. Chaung obtained a Bachelor of Science degree in chemical engineering from the National Taiwan University in Taiwan, in 1974. Dr. Chaung obtained a Master of Science degree in chemical engineering from st Virginia University in st Virginia, in 1978. Dr. Chaung obtained a Doctor of Science degree from the Massachetts Institute of Technology in Cambridge, Massachetts in 1982.- Tza Zen Chaung，在新药开发、药品良好生产规范（“GMP”）、制造工艺开发以及研发管理和战略方面拥有40年的经验。在担任Everfront Biotech Holding Company Limited的首席执行官之前，Chaung博士于1982年8月至1989年8月在新泽西州Rahway的默克公司（在美国和加拿大以外的国家称为默沙东）担任高级工程师，从事新药开发工作。1991年6月至1992年8月，他在新泽西州纳特利的Hoffmann-La Roche担任研究调查员。1992年8月至1995年1月在新泽西州新不伦瑞克的百时美施贵宝担任组长。从1995年1月至2023年1月，Chaung博士一直在美国和台湾担任制药和生物技术行业顾问。Chaung博士于1974年获得台湾国立台湾大学化学工程学理学学士学位。Chaung博士于1978年获得西弗吉尼亚州西弗吉尼亚大学化学工程理学硕士学位。Chaung博士于1982年在马萨诸塞州剑桥的麻省理工学院获得理学博士学位。
- Tza Zen Chaung serves as Chief Executive Officer and has served in this role since January 2023. Dr. Chaung has 40 years of experience in new drug development, pharmaceutical good manufacturing practice ("GMP"), manufacturing process development, and R&D management and strategy. Prior to serving as Chief Executive Officer, Dr. Chaung was Senior Engineer at Merck & Company in Rahway, New Jersey from August 1982 to August 1989, where he worked on new drug development. He worked as Research Investigator with Hoffmann La Roche in Nutley, New Jersey from June 1991 to August 1992. He worked as Group Leader with Bristol Myers Squibb in New Brunswick, New Jersey from August 1992 to January 1995. Dr. Chaung obtained a Bachelor of Science degree in chemical engineering from the National Taiwan University in Taiwan, in 1974. Dr. Chaung obtained a Master of Science degree in chemical engineering from st Virginia University in st Virginia, in 1978. Dr. Chaung obtained a Doctor of Science degree from the Massachetts Institute of Technology in Cambridge, Massachetts in 1982.
- Pi Chuan Chien
Pi Chuan Chien，现任台湾Excellence Management Consulting Co., Ltd.总经理，自2007年7月起担任该职务，致力于向企业引入复杂的成本管理系统，并提供与美国首次公开募股流程相关的财务会计咨询服务。Chien先生在财务报表审计和复杂的技术会计主题方面积累了丰富的经验。为此，Chien先生此前曾于2004年7月至2007年7月在台湾安永会计师事务所（Ernst & Young Global Limited）担任审计业务高级经理。Chien先生曾于1995年8月至2004年7月在BDO台湾公司担任经理。Chien先生于1995年毕业于台湾国立中兴大学，获会计学学士学位。
Pi Chuan Chien currently serves as Chief Financial Officer and has served as Chief Financial Officer since February 2023. Mr. Chien also currently serves as General Manager of Excellence Management Consulting Co., Ltd. in Taiwan, serving in this role since July 2007, where he works on introducing sophisticated cost management systems to binesses and provides financial accounting consulting services associated with U.S. initial public offering processes. Mr. Chien has accumulated considerable experience in financial statement audits and complex technical accounting topics. To this end, Mr. Chien previoly served as Senior Manager in the audit practice of Ernst & Young Global Limited in Taiwan from July 2004 to July 2007. Mr. Chien previoly served as Manager at BDO Taiwan from August 1995 to July 2004. Mr. Chien graduated from the National Chung Hsing University in Taiwan in 1995, with a Bachelor's degree in accounting.- Pi Chuan Chien，现任台湾Excellence Management Consulting Co., Ltd.总经理，自2007年7月起担任该职务，致力于向企业引入复杂的成本管理系统，并提供与美国首次公开募股流程相关的财务会计咨询服务。Chien先生在财务报表审计和复杂的技术会计主题方面积累了丰富的经验。为此，Chien先生此前曾于2004年7月至2007年7月在台湾安永会计师事务所（Ernst & Young Global Limited）担任审计业务高级经理。Chien先生曾于1995年8月至2004年7月在BDO台湾公司担任经理。Chien先生于1995年毕业于台湾国立中兴大学，获会计学学士学位。
- Pi Chuan Chien currently serves as Chief Financial Officer and has served as Chief Financial Officer since February 2023. Mr. Chien also currently serves as General Manager of Excellence Management Consulting Co., Ltd. in Taiwan, serving in this role since July 2007, where he works on introducing sophisticated cost management systems to binesses and provides financial accounting consulting services associated with U.S. initial public offering processes. Mr. Chien has accumulated considerable experience in financial statement audits and complex technical accounting topics. To this end, Mr. Chien previoly served as Senior Manager in the audit practice of Ernst & Young Global Limited in Taiwan from July 2004 to July 2007. Mr. Chien previoly served as Manager at BDO Taiwan from August 1995 to July 2004. Mr. Chien graduated from the National Chung Hsing University in Taiwan in 1995, with a Bachelor's degree in accounting.
- Yu Fang Hu
Yu Fang Hu，拥有工业制药领域的技能和知识，在组织发展和管理方面拥有超过25年的经验。Hu博士还与相关实体成功领导和协作了多个国际业务运营项目。在担任Everfront Biotech Holding Company Limited首席运营官之前，Hu博士曾于1999年4月至2023年9月担任台湾生物技术公司TTY Biopharm Co. Ltd.的研发高级经理、副总裁、高级副总裁等职务，其中一项关键职责是开发TTY Biopharm Co. Ltd.的产品线。Hu博士自2023年9月起担任TTY Biopharm Co. Ltd.顾问。Hu博士任职TTY Biopharm Co. Ltd.期间，为脂质体技术和长效微球注射液平台的开发做出贡献，在美国推出了AmBisome仿制药（脂质体两性霉素B注射液），并获得了强生的DoXIL产品（脂质体多柔比星注射液）全球代工项目。2019年5月至2021年2月，Hu博士担任PharmaEngine Inc.（台湾上市公司）总裁兼首席执行官。胡博士于2017年创立台湾临床阶段疗法开发公司EnhanX Biopharm Inc.，目前担任EnhanX Biopharm Inc.董事长。Hu博士于1986年获得台湾高雄医科大学药学理学学士学位。Hu博士于1992年获得圣约翰大学药学理学硕士学位。Hu博士于1999年获得圣约翰大学药学博士学位。
Yu Fang Hu serves as Chief Operating Officer and has served in this role since March 2024. Dr. Hu possesses skills and knowledge in the indtrial pharmaceutical field with over 25 years of experience in organizational development and management. Dr. Hu has also successfully led and collaborated on multiple international biness operation projects with relevant entities. Prior to serving as Chief Operating Officer, Dr. Hu served in the roles of R&D Senior Manager, Vice President, and Senior Vice President of TTY Biopharm Co. Ltd., a biotech company in Taiwan, from April 1999 to September 2023, where one of his key responsibilities was development of TTY Biopharm Co. Ltd.'s product line. Since September 2023, Dr. Hu served as a Consultant with TTY Biopharm Co. Ltd. During his TTY Biopharm Co. Ltd. employment, Dr. Hu contributed to the development of liposome technology and long acting microsphere injection platforms, launched the AmBisome generic drug (Liposomal Amphotericin B Injection) in the United States, and obtained the global contract manufacturing project for Doxil product (Liposomal Doxorubicin Injection) from Johnson & Johnson. From May 2019 to February 2021, Dr. Yu served as President & CEO of PharmaEngine Inc. (a listed company in Taiwan). Dr. Hu founded EnhanX Biopharm Inc., a clinical stage therapy development company in Taiwan, in 2017 and currently serves as Chairman of EnhanX Biopharm Inc. Dr. Hu obtained a Bachelor of Science degree in pharmacy from Kaohsiung Medical University in Taiwan in 1986. Dr. Hu obtained a Master of Science degree in pharmacy from St. John's University in 1992. Dr Hu. obtained a Ph.D. degree in pharmacy from St. John's University in 1999.- Yu Fang Hu，拥有工业制药领域的技能和知识，在组织发展和管理方面拥有超过25年的经验。Hu博士还与相关实体成功领导和协作了多个国际业务运营项目。在担任Everfront Biotech Holding Company Limited首席运营官之前，Hu博士曾于1999年4月至2023年9月担任台湾生物技术公司TTY Biopharm Co. Ltd.的研发高级经理、副总裁、高级副总裁等职务，其中一项关键职责是开发TTY Biopharm Co. Ltd.的产品线。Hu博士自2023年9月起担任TTY Biopharm Co. Ltd.顾问。Hu博士任职TTY Biopharm Co. Ltd.期间，为脂质体技术和长效微球注射液平台的开发做出贡献，在美国推出了AmBisome仿制药（脂质体两性霉素B注射液），并获得了强生的DoXIL产品（脂质体多柔比星注射液）全球代工项目。2019年5月至2021年2月，Hu博士担任PharmaEngine Inc.（台湾上市公司）总裁兼首席执行官。胡博士于2017年创立台湾临床阶段疗法开发公司EnhanX Biopharm Inc.，目前担任EnhanX Biopharm Inc.董事长。Hu博士于1986年获得台湾高雄医科大学药学理学学士学位。Hu博士于1992年获得圣约翰大学药学理学硕士学位。Hu博士于1999年获得圣约翰大学药学博士学位。
- Yu Fang Hu serves as Chief Operating Officer and has served in this role since March 2024. Dr. Hu possesses skills and knowledge in the indtrial pharmaceutical field with over 25 years of experience in organizational development and management. Dr. Hu has also successfully led and collaborated on multiple international biness operation projects with relevant entities. Prior to serving as Chief Operating Officer, Dr. Hu served in the roles of R&D Senior Manager, Vice President, and Senior Vice President of TTY Biopharm Co. Ltd., a biotech company in Taiwan, from April 1999 to September 2023, where one of his key responsibilities was development of TTY Biopharm Co. Ltd.'s product line. Since September 2023, Dr. Hu served as a Consultant with TTY Biopharm Co. Ltd. During his TTY Biopharm Co. Ltd. employment, Dr. Hu contributed to the development of liposome technology and long acting microsphere injection platforms, launched the AmBisome generic drug (Liposomal Amphotericin B Injection) in the United States, and obtained the global contract manufacturing project for Doxil product (Liposomal Doxorubicin Injection) from Johnson & Johnson. From May 2019 to February 2021, Dr. Yu served as President & CEO of PharmaEngine Inc. (a listed company in Taiwan). Dr. Hu founded EnhanX Biopharm Inc., a clinical stage therapy development company in Taiwan, in 2017 and currently serves as Chairman of EnhanX Biopharm Inc. Dr. Hu obtained a Bachelor of Science degree in pharmacy from Kaohsiung Medical University in Taiwan in 1986. Dr. Hu obtained a Master of Science degree in pharmacy from St. John's University in 1992. Dr Hu. obtained a Ph.D. degree in pharmacy from St. John's University in 1999.
- Jen Wei Liu
Jen Wei Liu，现任子公司临床研究总监，自2020年9月起担任该职务。2019年12月至2020年8月，Liu博士在子公司担任研究员。Liu博士拥有十年新药研发、临床管理、战略规划经验。Liu博士参与了FDA和TFDA监管的三（3）项临床试验，在毒理学和药代动力学研究方面经验丰富。Liu博士曾于2014年至2018年担任包括A +产业创新研发计划（项目编号：103-EC-17-A-20-I1-0004）在内的国家级项目的首席研究员，总预算超过400万美元。Liu博士科学底蕴深厚，发表过十余篇文章。Liu博士于2005年获得台湾国立中山大学生物科学系生物科学学士学位。Liu博士于2008年获得国立东华大学生物技术研究所生物技术硕士学位。Liu博士于2013年获得台湾国立中兴大学生命科学博士学位。
Jen Wei Liu serves as the Chief Scientific Officer of the Company and has served in this role since March 2024. Dr. Liu also currently serves as Director of the Clinical Research Director of the Subsidiary and has served in this role since September 2020. From December 2019 to August 2020, Dr. Liu served as Research Fellow at the Subsidiary. Dr. Liu has ten years of experience in new drug development, clinical management, and strategic planning. Dr. Liu has been involved in three (3) clinical trials regulated by the FDA and TFDA and is experienced in toxicology and pharmacokinetic studies. Dr. Liu has served as the principal investigator of national level projects including A+ Indtrial Innovation R&D Program (project number: 103 EC 17 A 20 I1 0004) from2014 to 2018, with a total budget of over $4 million. Dr. Liu has a strong scientific background and has published more than ten articles. Dr. Liu obtained a Bachelor's degree in biological science from the department of biological science at National Sun Yat Sen University in Taiwan in 2005. Dr. Liu obtained a Master's degree in biotechnology from the Institute of Biotechnology at National Dong Hwa University in 2008. Dr. Liu obtained a Ph.D. degree in life sciences from the National Chung Hsing University in Taiwan, in 2013.- Jen Wei Liu，现任子公司临床研究总监，自2020年9月起担任该职务。2019年12月至2020年8月，Liu博士在子公司担任研究员。Liu博士拥有十年新药研发、临床管理、战略规划经验。Liu博士参与了FDA和TFDA监管的三（3）项临床试验，在毒理学和药代动力学研究方面经验丰富。Liu博士曾于2014年至2018年担任包括A +产业创新研发计划（项目编号：103-EC-17-A-20-I1-0004）在内的国家级项目的首席研究员，总预算超过400万美元。Liu博士科学底蕴深厚，发表过十余篇文章。Liu博士于2005年获得台湾国立中山大学生物科学系生物科学学士学位。Liu博士于2008年获得国立东华大学生物技术研究所生物技术硕士学位。Liu博士于2013年获得台湾国立中兴大学生命科学博士学位。
- Jen Wei Liu serves as the Chief Scientific Officer of the Company and has served in this role since March 2024. Dr. Liu also currently serves as Director of the Clinical Research Director of the Subsidiary and has served in this role since September 2020. From December 2019 to August 2020, Dr. Liu served as Research Fellow at the Subsidiary. Dr. Liu has ten years of experience in new drug development, clinical management, and strategic planning. Dr. Liu has been involved in three (3) clinical trials regulated by the FDA and TFDA and is experienced in toxicology and pharmacokinetic studies. Dr. Liu has served as the principal investigator of national level projects including A+ Indtrial Innovation R&D Program (project number: 103 EC 17 A 20 I1 0004) from2014 to 2018, with a total budget of over $4 million. Dr. Liu has a strong scientific background and has published more than ten articles. Dr. Liu obtained a Bachelor's degree in biological science from the department of biological science at National Sun Yat Sen University in Taiwan in 2005. Dr. Liu obtained a Master's degree in biotechnology from the Institute of Biotechnology at National Dong Hwa University in 2008. Dr. Liu obtained a Ph.D. degree in life sciences from the National Chung Hsing University in Taiwan, in 2013.
- Yuan Sheng Li
Yuan Sheng Li，现任子公司研究发展与制造部总监，自2018年8月起担任该职务。2017年10月至2018年7月，Li博士在子公司担任研究员。2013年7月至2017年9月，Li博士担任子公司副研究员。Li博士拥有十年新药开发、药物化学、制造与控制、研发管理和战略经验，其经验是自2013年7月起受雇于子公司期间获得的。Li博士曾在干细胞治疗、药物配方、神经元科学领域共同撰写并发表论文十篇。Li博士于2006年毕业于台湾中国文化大学化学工程系，获化学工程学士学位。Li博士于2016年毕业于台湾国立东华大学，获生物科技博士学位。
Yuan Sheng Li serves as the Chief Technology Officer of the Company and has served in this role since March 2024. Dr. Li also currently serves as Director of the Research, Development and Manufacturing Department for the Subsidiary and has served in this role since August 2018. From October 2017 to July 2018, Dr. Li served as Research Fellow at the Subsidiary. From July 2013 to September 2017, Dr. Li served as Associate Research Fellow at the Subsidiary. Dr. Li has ten years of experience in new drug development, pharmaceutical chemistry, manufacturing and controls, R&D management and strategy and his experience was acquired during his period of employment with the Subsidiary since July 2013.Dr. Li has co written and published ten papers for stem cell therapy, drug formulation, and neuron science. Dr. Li graduated with a Bachelor's degree in chemical engineering from the chemical engineering department at Chinese Culture University in Taiwan in 2006. Dr. Li graduated from the National Dong Hwa University in Taiwan, with a Ph.D. degree in biotechnology, in 2016.- Yuan Sheng Li，现任子公司研究发展与制造部总监，自2018年8月起担任该职务。2017年10月至2018年7月，Li博士在子公司担任研究员。2013年7月至2017年9月，Li博士担任子公司副研究员。Li博士拥有十年新药开发、药物化学、制造与控制、研发管理和战略经验，其经验是自2013年7月起受雇于子公司期间获得的。Li博士曾在干细胞治疗、药物配方、神经元科学领域共同撰写并发表论文十篇。Li博士于2006年毕业于台湾中国文化大学化学工程系，获化学工程学士学位。Li博士于2016年毕业于台湾国立东华大学，获生物科技博士学位。
- Yuan Sheng Li serves as the Chief Technology Officer of the Company and has served in this role since March 2024. Dr. Li also currently serves as Director of the Research, Development and Manufacturing Department for the Subsidiary and has served in this role since August 2018. From October 2017 to July 2018, Dr. Li served as Research Fellow at the Subsidiary. From July 2013 to September 2017, Dr. Li served as Associate Research Fellow at the Subsidiary. Dr. Li has ten years of experience in new drug development, pharmaceutical chemistry, manufacturing and controls, R&D management and strategy and his experience was acquired during his period of employment with the Subsidiary since July 2013.Dr. Li has co written and published ten papers for stem cell therapy, drug formulation, and neuron science. Dr. Li graduated with a Bachelor's degree in chemical engineering from the chemical engineering department at Chinese Culture University in Taiwan in 2006. Dr. Li graduated from the National Dong Hwa University in Taiwan, with a Ph.D. degree in biotechnology, in 2016.